BB Biotech: 2024 Results and Dividend Proposal Overview

BB Biotech AG announced preliminary 2024 results revealing challenges and strategic moves within the volatile biotech sector. The company reported a total return of -13.5% in CHF and -14.1% in EUR for its shares, reflecting a challenging year including a CHF 2.00 dividend paid in March 2024. Despite share price declines, the net profit reached CHF 76 million, a significant recovery from the CHF 207 million loss in 2023.

The fourth quarter of 2024 also showed mixed results. The share price return was -2.7% in CHF and -3.5% in EUR, while the NAV rose by +2.7% in CHF. A notable aspect was the persistent 15.2% discount of the share price to NAV, indicative of cautious investor sentiment.

The Board proposed a regular dividend of CHF 1.80 per share for 2025, suggesting a steady 5% yield. This aligns with BB Biotech's established dividend policy and reflects a balanced approach to reinvesting for long-term biotech sector growth.